131 related articles for article (PubMed ID: 25895097)
1. Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients.
Romano S; D'Angelillo A; Staibano S; Simeone E; D'Arrigo P; Ascierto PA; Scalvenzi M; Mascolo M; Ilardi G; Merolla F; Jovarauskaite E; Romano MF
Pigment Cell Melanoma Res; 2015 Jul; 28(4):442-52. PubMed ID: 25895097
[TBL] [Abstract][Full Text] [Related]
2. Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients.
Troiani T; Giunta EF; Tufano M; Vigorito V; Arrigo P; Argenziano G; Ciardiello F; Romano MF; Romano S
Br J Cancer; 2020 Jun; 122(12):1782-1790. PubMed ID: 32317723
[TBL] [Abstract][Full Text] [Related]
3. The FKBP51s Splice Isoform Predicts Unfavorable Prognosis in Patients with Glioblastoma.
Giordano C; Marrone L; Romano S; Della Pepa GM; Donzelli CM; Tufano M; Capasso M; Lasorsa VA; Quintavalle C; Guerri G; Martucci M; Auricchio A; Gessi M; Sala E; Olivi A; Romano MF; Gaudino S
Cancer Res Commun; 2024 May; 4(5):1296-1306. PubMed ID: 38651817
[TBL] [Abstract][Full Text] [Related]
4. FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy.
Romano S; Simeone E; D'Angelillo A; D'Arrigo P; Russo M; Capasso M; Lasorsa VA; Zambrano N; Ascierto PA; Romano MF
Cancer Immunol Immunother; 2017 Sep; 66(9):1143-1151. PubMed ID: 28434031
[TBL] [Abstract][Full Text] [Related]
5. Alternative splicing of FKBP5 gene exerts control over T lymphocyte expansion.
Marrone L; D'Agostino M; Cesaro E; di Giacomo V; Urzini S; Romano MF; Romano S
J Cell Biochem; 2023 Jan; ():. PubMed ID: 36645880
[TBL] [Abstract][Full Text] [Related]
6. A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.
D'Arrigo P; Russo M; Rea A; Tufano M; Guadagno E; Del Basso De Caro ML; Pacelli R; Hausch F; Staibano S; Ilardi G; Parisi S; Romano MF; Romano S
Oncotarget; 2017 Sep; 8(40):68291-68304. PubMed ID: 28978117
[TBL] [Abstract][Full Text] [Related]
7. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
[TBL] [Abstract][Full Text] [Related]
8. Scaffold proteins of cancer signaling networks: The paradigm of FK506 binding protein 51 (FKBP51) supporting tumor intrinsic properties and immune escape.
Marrone L; D'Agostino M; Giordano C; Giacomo VD; Urzini S; Malasomma C; Gammella MP; Tufano M; Romano S; Romano MF
Oncol Res; 2023; 31(4):423-436. PubMed ID: 37415743
[TBL] [Abstract][Full Text] [Related]
9. Identification of genes differentially expressed in melanoma sublines derived from a single surgical specimen characterised by different sensitivity to cytotoxic T-lymphocyte activity.
Kocher T; Schraml P; Spagnoli GC; Harder F; Heberer M
Schweiz Med Wochenschr; 2000 Apr; 130(17):617-24. PubMed ID: 10829299
[TBL] [Abstract][Full Text] [Related]
10. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.
Madore J; Vilain RE; Menzies AM; Kakavand H; Wilmott JS; Hyman J; Yearley JH; Kefford RF; Thompson JF; Long GV; Hersey P; Scolyer RA
Pigment Cell Melanoma Res; 2015 May; 28(3):245-53. PubMed ID: 25477049
[TBL] [Abstract][Full Text] [Related]
12. Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes.
Chapon M; Randriamampita C; Maubec E; Badoual C; Fouquet S; Wang SF; Marinho E; Farhi D; Garcette M; Jacobelli S; Rouquette A; Carlotti A; Girod A; Prévost-Blondel A; Trautmann A; Avril MF; Bercovici N
J Invest Dermatol; 2011 Jun; 131(6):1300-7. PubMed ID: 21346771
[TBL] [Abstract][Full Text] [Related]
13. Molecular Aspects of FKBP51 that Enable Melanoma Dissemination.
D'Angelillo A; Staibano S; Russo M; Romano MF; Romano S
Curr Mol Pharmacol; 2015; 9(2):141-7. PubMed ID: 25986563
[TBL] [Abstract][Full Text] [Related]
14. Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5.
Sensi M; Pietra G; Molla A; Nicolini G; Vegetti C; Bersani I; Millo E; Weiss E; Moretta L; Mingari MC; Anichini A
Int Immunol; 2009 Mar; 21(3):257-68. PubMed ID: 19181932
[TBL] [Abstract][Full Text] [Related]
15. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P
Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561
[TBL] [Abstract][Full Text] [Related]
16. PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease.
Krönig H; Julia Falchner K; Odendahl M; Brackertz B; Conrad H; Muck D; Hein R; Blank C; Peschel C; Haller B; Schulz S; Bernhard H
Int J Cancer; 2012 May; 130(10):2327-36. PubMed ID: 21717461
[TBL] [Abstract][Full Text] [Related]
17. T-cell receptor repertoire of lymphocytes infiltrating cutaneous melanoma is predominated by V alpha specificities present in T-cells of normal human skin.
Strohal R; Paucz L; Pehamberger H; Stingl G
Cancer Res; 1994 Sep; 54(17):4734-9. PubMed ID: 8062272
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
Droeser RA; Hirt C; Viehl CT; Frey DM; Nebiker C; Huber X; Zlobec I; Eppenberger-Castori S; Tzankov A; Rosso R; Zuber M; Muraro MG; Amicarella F; Cremonesi E; Heberer M; Iezzi G; Lugli A; Terracciano L; Sconocchia G; Oertli D; Spagnoli GC; Tornillo L
Eur J Cancer; 2013 Jun; 49(9):2233-42. PubMed ID: 23478000
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; Mandalà M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of infiltrating lymphocytes in choroidal melanoma].
Ohta K; Norose K; Ishii K
Nippon Ganka Gakkai Zasshi; 1995 Nov; 99(11):1277-82. PubMed ID: 8533659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
